Innova Captab Limited is an integrated pharmaceutical company in India with a
presence across the pharmaceuticals value chain including research and
development, manufacturing, drug distribution and marketing and
exports. Since our inception in 2006 with a small base, Innova Captab Limited have grown strength to strength and for last more than 15
years, Innova Captab Limited are catering to top Indian
pharmaceuticals companies including 10 of the top 10, and 14 of the top 15. Company have license to manufacture products through
two state of the art manufacturing facilities while maintaining WHO-GMP, EU-GMP
and other major registrations. With the support of our world class
manufacturing facilities and a reliable supply value chain, Innova Captab Limited are continuously thriving to maintain highly
efficient operations. The foundation of Company is our in-house research and
development (R&D).
which helps to focus on to build an increasingly complex product portfolio and
attract and retain customers. We proudly possess a strong team of 1000+
employees.
Innova Captab positive :
· Integrated Business Model: InnovaCaptab offers a diverse range of services, making it less susceptible to
fluctuations in any single segment.
· Strong CDMO Presence: The company is a
leading Contract Development and Manufacturing Organization (CDMO) in India,
with over 182 clients including renowned names like Cipla and Glenmark.
· Growing Branded Generics Business: InnovaCaptab is expanding its domestic and international markets for branded
generics, offering affordable alternatives to branded drugs.
· Robust Financial Performance: The
company has demonstrated consistent revenue growth and profitability,
attracting potential investors.
Innova Captab Risk :
· Competition: The Indian pharmaceutical
market is highly competitive, with both domestic and multinational players
vying for market share.
· Dependence on CDMO Business: While
lucrative, a significant portion of Innova Captab's revenue comes from the CDMO
segment, exposing it to potential client losses or market changes.
· International Expansion: Success in
overseas markets, particularly in regulated markets like the US and Europe,
requires stringent compliance and regulatory hurdles.
· Valuation Concerns: Some analysts
suggest the company's recent IPO might have priced it at a premium.
Highlight of Balance Sheet:
· 1. Strong Revenue Growth: Revenue grew from Rs. 800.5 crore in FY22 to Rs. 1,118.6 crore in FY23, a 40% increase.
· 2. Profitability: Net profit rose from Rs. 64 crore in FY22 to Rs. 101.1 crore in FY23, a 58% increase.
· 3. Margins: EBITDA margin stands at 14.7%, while PAT margin is 7.3%.
· 4. Debt: Net debt-to-equity ratio is
1.0, which is moderately high.
Income Statement:
· Revenue:
o FY22: Rs. 800.5 crore
o FY23: Rs. 1,118.6 crore (40% YoY growth)
· EBITDA:
o FY22: Rs. 118.2 crore
o FY23: Rs. 164.5 crore (38% YoY growth)
· PAT:
o FY22: Rs. 64 crore
o FY23: Rs. 101.1 crore (58% YoY growth)
· Margins:
o EBITDA margin: 14.7%
o PAT margin: 7.3%
Assets and Liabilities :
·
Total Assets: Rs. 1,425.2 crore
·
Current Assets: Rs. 601.9 crore
·
Non-Current Assets: Rs. 823.3
crore
·
Total Liabilities: Rs. 1,292.2
crore
·
Current Liabilities: Rs. 545.7
crore
·
Non-Current Liabilities: Rs. 746.5
crore
·
Net Debt: Rs. 133 crore
·
Debt-to-Equity Ratio: 1.0
Cash Flow Statement:
·
Operating Cash Flow: Rs. 192.3
crore
·
Investing Cash Flow: Rs. (228.4) crore
·
Financing Cash Flow: Rs. 101.9
crore
Key Financial Ratios:
·
Current Ratio: 1.10
·
Quick Ratio: 0.81
·
Return on Equity (ROE): 24.58%
·
Return on Assets (ROA): 7.26%
·
Interest Coverage Ratio: 7.79
IPO date |
21/12/2023 to
26/12/2023 |
Price band |
Rs. 426 – Rs .
448 |
Lot size |
33 shares |
Basis of
Allotment |
27/12/2023 |
Date of refund
& share credit |
28/12/2023 |
Date of listing |
29/12/2023 |
GMP |
+50 to -50 |
Innova Captab's financials based on publicly available information. It is not intended as investment advice. Please conduct your own research and due diligence before making any investment decisions.
#ipogmps #ipogmp #mediassist #mediassist4u #mediassistipo #nseipo #nseipogmp #nseiporque #ñseiporque #nseiportag🤡 #nseipostei #StockMarketInvestment #stockmarketnewstoday #stockmarketcrash #indianstockmarketguide #indianstockmarketmemes #indianstockmarkets #indianstockmarketnews #futureoptionmacedonia #futureoptionsintraday #futureoptionstrading #futureoptionals #futureoptions #futureoption #sensexbasicsbysita #sensexnifty50 #sensextoday #sensexnift #sensexindia #sensexhigh
No comments:
Post a Comment